| ¿µ¹® | basal metabolic rate(BMR) | ÇÑ±Û | ±âÃÊ´ë»çÀ² |
|---|---|---|---|
| ¼³¸í | Ç¥ÁØ ±âÃÊ´ë»ç·®°ú ºñ±³ÇßÀ» ¶§ °³Ã¼ ±âÃÊ´ë»ç·®ÀÌ º¸ÀÌ´Â ÆíÂ÷¸¦ Ç¥½ÃÇÏ´Â Áö¼ö. ±âÃÊ´ë»ç·®Àº »ý¸íÀ» À¯ÁöÇϴµ¥ ÇÊ¿äÇÑ ÃÖ¼ÒÇÑÀÇ ¿¡³ÊÁö ´ë»ç·®À̸ç, ¼º°ú ¿¬·ÉÀÌ µ¿ÀÏÇÑ °Ç°ÀÎÀÇ ±âÃÊ´ë»ç·®Àº üǥ¸éÀû¿¡ ºñ·ÊÇÑ´Ù. À̰ÍÀ» üǥ¸éÀûÀÇ ¹ýÄ¢À̶ó°í Çϸç, 1882³â µ¶ÀÏÀÇ ´ë»ç»ý¸®ÇÐÀÚ M. ºê·ç³Ê¿¡ ÀÇÇØ Á¦Ã¢µÇ¾ú´Ù. üǥ¸éÀûÀº ½ÅÀå°ú üÁß¿¡ ÀÇÇØ »êÃâµÈ´Ù. µû¶ó¼ ¼º-¿¬·É-½ÅÀå-üÁßÀ» ¾Ë¸é Ç¥ÁرâÃÊ·® Y°¡ »êÃâµÇ°í ½ÇÁ¦ÀÇ ±âÃÊ´ë»ç·® X´Â »ê¼Ò¼Òºñ·®°ú ÀÌ»êÈź¼Ò ¹ß»ý·®¿¡¼ »êÃâµÈ´Ù. ±×¸®°í X¿Í YÀÇ Â÷À̸¦ Y·Î ³ª´« °ª(%)À» ±âÃÊ´ë»çÀ²À̶ó°í ÇÑ´Ù. °æÇèÀûÀ¸·Î ¾òÀº BMRÀÇ °£´ÜÇÑ ÃøÁ¤¹ýµµ ÀÖÀ¸¸ç ´ÙÀ½°ú °°Àº ½ÄÀ¸·Î ±¸ÇÑ´Ù. ÀÌ ½Ä¿¡¼ ¸ÆÆøÀ̶õ ÃÖ°íÇ÷¾Ð°ú ÃÖÀúÇ÷¾ÐÀÇ Â÷¸¦ ¸»ÇÑ´Ù. BMR(%)=0.75(1ºÐ ¸Æ¹Ú¼ö + 0.74¡¿¸ÆÆø)£72. BMRÀÌ 10% À̳»À̸é Á¤»ó¹üÀ§, +10% ÀÌ»óÀÌ¸é ±âÃÊ´ë»çÇ×Áø, £10% ÀÌÇÏÀÌ¸é ±âÃÊ´ë»ç ÀúÇ϶ó°í ÇÑ´Ù. ±âÃÊ´ë»ç´Â °øº¹½Ã(½ÄÈÄ 10½Ã°£ °æ°ú)¿¡ ¾ÈÁ¤µÈ »óÅ¿¡¼ ´ÜÀ§ ½Ã°£´ç ÀÌ¿ëµÇ´Â ¿¡³ÊÁöÀÇ ¾ç, Áï, ÇÑ ½Ã°£´ç, ¸ö Ç¥¸éÀÇ 1m2´ç ¶Ç´Â ¸ö¹«°Ô 1kg ´ç Ä®·Î¸®·Î ³ªÅ¸³½´Ù. À̰ÍÀº °³Àο¡ µû¶ó ´Ù¸£¸ç Àå±â°£¿¡´Â °ÅÀÇ º¯È°¡ ¾øÁö¸¸ Áúº´ µîÀ¸·Î ÀÎÇØ º¯µ¿µÈ´Ù. ½ÇÃøÇÑ ±âÃÊ´ë»ç¸¦ Ç¥ÁØÄ¡¿Í ºñ±³ÇÔÀ¸·Î½á Áúº´ÀÇ Áø´Ü µî¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖ´Ù BMR=(½ÇÃøÄ¡-Ç¥ÁØÄ¡)/Ç¥ÁØÄ¡ ¡¿100(%)·Î ³ªÅ¸³½´Ù. |
||
| ¿µ¹® | VDRL(venereal disease research laboratory) | ÇÑ±Û | ¼ºº´ ¿¬±¸½ÇÇè½Ç |
|---|---|---|---|
| ¼³¸í | ¸Åµ¶±ÕÀÇ reagin¿¡ ´ëÇÑ Ç×ü. ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ¿Í Ä¡·áÈ¿°ú ÆÇÁ¤¿¡µµ »ç¿ëµÈ´Ù. ¸Åµ¶¿Ü¿¡µµ Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶Æ¼½º°üÀý¿° µî¿¡¼µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | Dilatation and Curettage(D & C) | ÇÑ±Û | Àڱñܾ¼ú, ÀڱøñÈ®Àå |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀ̶õ žư¡ ¼öÅÂµÇ¾î¼ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇÏ´Â °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ žƸ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ÀڱøñÀ» È®Àå½ÃÄÑ¾ß ÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇÏ´Â ¹ý°ú ¼¼È÷ È®ÀåÀ» ½ÃµµÇÏ´Â 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ ÀÖ¾î¼ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼¼È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇÏ´Â ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃÊ·Î ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î õõÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼ ÀڱüÓÀÇ º´º¯À̳ª ÀÓ½ÅµÈ Å¾Ƹ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀÇ Ã¤Ãë ¹× Á¦°Å¸¦ À§Çؼµµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. ÀÌ´Â ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà ³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. |
||
| ¿µ¹® | upper GI series | ÇÑ±Û | »óºÎÀ§Àå°üÁ¶¿µ¼ú |
|---|---|---|---|
| ¼³¸í | X-¼± »çÁø¿¡¼ Àß ³ªÅ¸³ª´Â Á¶¿µÁ¦(¹æ»ç¼±ÃÔ¿µ»ó¿¡¼ ÇϾé°Ô ³ªÅ¸³ª ÁÖÀ§Á¶Á÷°ú °¨º°ÀÌ ¿ëÀÌÇÏ´Ù)¸¦ ¼·ÃëÇÑ ÈÄ ½Äµµ, À§, »ùâÀÚ, ÀÛÀºÃ¢ÀÚ»óºÎ±îÁö X-¼± ÃÔ¿µÇϹǷνá, ±×°÷ ¼ÒȰü³»ÀÇ ÀÌ»óº´ÅÍ¿©ºÎ¸¦ °Ë»çÇÏ´Â °Í. Á¶¿µÁ¦´Â ÁÖ·Î ¹Ù·ýÀ» »ç¿ëÇÏ¸ç ´õ ¼±¸íÇÑ ¿µ»óÀ» ¾ò±âÀ§ÇØ ¹ßÆ÷Á¦¸¦ ÇÔ²² ¼·ÃëÇÏ¿© ¹Ù·ý°ú °ø±âÀÇ ÀÌÁßÁ¶¿µÃÔ¿µÀ» Çϱ⵵ ÇÑ´Ù. ½Äµµ¾Ï, À§¾Ï ¹× ¼Òȼº±Ë¾ç°ú ±×¹Û¿¡ ´Ù¾çÇÑ º´º¯ÀÇ Áø´Ü¿¡ È¿°úÀûÀ¸·Î »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | small bowel series | ÇÑ±Û | ÀÛÀºÃ¢ÀÚ Á¶¿µ¼ú, ¼ÒÀå Á¶¿µ¼ú |
|---|---|---|---|
| ¼³¸í | ¹æ»ç¼± Á¶¿µÁ¦(¹æ»ç¼±°Ë»ç¿¡¼ ´Ù¸¥ ºÎÀ§¿Í ´ëÁ¶µÇ´Â ¾ÆÁÖ Èò»öÀ» ¶ì´Â ¹°Áú)ÀÎ ¹Ù·ýÀ» ¼·ÃëÇÑ µÚ, ÃÔ¿µÇÏ´Â ÀÛÀºÃ¢ÀÚÀÇ ±âº»ÀûÀÎ ¹æ»ç¼± °Ë»ç·Î¼, ¹æ¹ýÀº 200~300mLÀÇ ¹Ù·ýÀ» ¸ÔÀºµÚ ¹Ù·ýÀÌ ÀÛÀº âÀÚ¸¦ Åë°úÇÏ´Â µ¿¾È Á¤±ÔÀû °£°ÝÀ¸·Î ¹æ»ç¼± »çÁøÀ» ÂïÀ½. ÀϹÝÀûÀ¸·Î 2~3½Ã°£ÀÌ °É¸². |
||
| GIS | gas in stomach; gastrointestinal series; geographic information system; guaranteed income supplement... |
|---|---|
| HCTS | high cholesterol and tocopherol supplement |
| HPS | Hantavirus pulmonary syndrome; hematoxylin, phloxin, and saffron; Hermansky-Pudlak syndrome; high-pr... |
| SS | disulfide; sacrosciatic; saline soak; saline solution; saliva sample; saliva substitute; Salmonella-... |
| FSH/LR-RH | follicle-stimulating hormone and luteinizing hormone releasing hormone |
| ECGS | Endothelial Cell Growth Supplement |
|---|---|
| SEC | Series elastic component |
| AHCPR | Agency for Health Care Policy and Research |
| AHRQ | Agency for Health Care Research and Quality |
| CBER | Center for Biologics Evaluation and Research |
seriflux
| supplement | Something that supplies a want or make an addition: something that completes, adds a finishing touch or brings closer to completion or a desired state. (18 Nov 1997) |
|---|---|
| hormones, hormone substitutes, and hormone antagonists | A collective grouping for both naturally occurring and synthetic hormones, substitutes, and antagonists. (12 Dec 1998) |
| united states agency for health care policy and research | An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research. (12 Dec 1998) |
| nutritional and metabolic diseases | A collective term for nutritional disorders (result of poor assimilation or utilization of food) and metabolic disorders (result of poor metabolism or inherited enzyme abnormality). (12 Dec 1998) |
| receptors, pituitary hormone-regulating hormone | Cell surface receptors that bind the hypothalamic hormones regulating pituitary cell differentiation, proliferation, and hormone synthesis and release, including the pituitary-releasing and release-inhibiting hormones. The pituitary hormone-regulating hormones are also released by cells other than hypothalamic neurons, and their receptors also occur on non-pituitary cells, especially brain neurons, where their role is less well understood. Receptors for dopamine, which is a prolactin release-inhibiting hormone as well as a common neurotransmitter, are not included here. (12 Dec 1998) |
| growth hormone inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| growth hormone-regulating hormone | <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin). (18 Nov 1997) |
| growth hormone-releasing hormone | <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone. Synonym: somatoliberin, growth hormone-releasing factor. (20 Sep 2002) |
| follicle-stimulating hormone-releasing hormone | A decapeptide of hypothalamic origin capable of accelerating pituitary secretion of follitropin. Synonym: follicle-stimulating hormone-releasing factor, follicle-stimulating hormone-releasing hormone. Origin: follicle-stimulating hormone + L. Libero, to free, + -in (05 Mar 2000) |
| luteinizing hormone/follicle-stimulating hormone-releasing factor | gonadotrophin-releasing hormone |
| luteinizing hormone-releasing hormone | A hormone that controls sex hormones in men and women. Also called lhrh. (12 Dec 1998) |
| aromatic series | All the compounds derived from benzene, or similar cyclic compounds that obey Huckel's rule, distinguished from those compounds that are acyclic or that contain rings that lack the conjugated double bond structure characteristic of benzene. (05 Mar 2000) |
| granulocytic series | <haematology> The cells in the several stages of development in the bone marrow leading to the mature granulocyte of the circulation, e.g., myeloblasts, different stages of the myelocyte, granulocytes. (05 Mar 2000) |
| myeloid series | The granulocytic and the erythrocytic series. (05 Mar 2000) |
| Hofmeister series | <chemistry> The series of cations Magnesium, Calcium, Sr2+, Ba2+, Li+, Na+, K+, Rb+, Cs+, and of anions citrate3-, tartrate2-, SO42-, acetate-, NO3-, CIO3-, I-, CNS- (among others). Each series is arranged in order of decreasing ability to: 1) precipitate the dispersed substance of lyophilic soltions; 2) "salt out" organic substances (e.g., aniline, ethyl acetate) from aqueous solutions; or 3) inhibit the swelling of gels. These effects, among other related ones, are ascribable to the abstraction and binding of water by these ions (i.e., hydration), which also decreases in the orders given, so that (in the monovalent cation series) Li+, with the smallest crystal radius, has the largest hydrated radius, and vice versa for Cs+. Synonym: lyotropic series. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|